OPUS has extensive experience working with life science and high-tech companies building communications programs that strengthen and complement company business goals.
Our Focus
We work with companies to tell their stories of innovation, perseverance and value.
We create strategies for connecting with critical constituencies such as news media, opinion leaders, government officials, investors, and business partners.
We help companies, their people and technology stand out from the crowd.
Our Work
Our communications expertise is grounded in the ability to write clear, concise and compelling copy, forming the foundation for the services we provide, such as:
Strategic Communications Consulting
Press Releases & Press Placement
Digital & Marketing
Websites, Branding, Social Media, Investor Decks, Fact Sheets
What We Do
Our communications expertise is grounded in the ability to write clear, concise and compelling copy, forming the foundation for the services we provide, such as:
Public & Investor Relations
CEO and Company Reputation Management and Government Affairs Support
Outreach to Investors, Business Partners, Regulatory Affairs Experts and Advocacy Groups
Website Development, Brand Identity, Investor Decks, Social Media Expertise
Opus provides a full range of biotech public relations and marketing services for emerging and established companies.
Reputation management
Ongoing strategic media and communications counsel
Press releases writing and editing
Media outreach
Message development
Investor outreach preparation and presentations
Website reviews
Local, State and Federal lobbying
R & D Bioethics program development
Marketing Services thru Opus Affiliate
Website Design & Content Management
Brand Identity/Logo Design
Investor Decks
Infographics, One-sheets, Videos
Social Media Expertise
Who We Are
Daniel Eramian served as the first vice president of communications for the Biotechnology Innovation Organization (BIO) during the industry’s transformation from fascinating science to global health care innovator. Eramian and BIO played a major role in helping hundreds of emerging life sciences companies communicate the benefits and value of the industry to multiple audiences as well as improving the investment climate. Eramian has also managed challenging communications and investor relations programs at individual public and private biotech companies and served on their Management Boards. He knows the business of life science companies. Eramian has also been chief spokesmen for government leaders including the Attorney General of the United States.
Charles Craig has been on the front lines of the biotech revolution as president of Georgia Bio and as a writer, editor and communicator for the Biotechnology Innovation Organization (BIO), BioWorld Today and annual Ernst & Young Global Biotechnology Report. During his 30-year career, he also worked as a writer and editor for mainstream newspapers, magazines, and television news. In addition, Craig has a Master of Arts degree in bioethics from Emory University, writes and lectures on health care and clinical research ethics, and has experience building a framework for addressing bioethical issues.
Penny Jo Welsch, founder of Opus affiliate PJWCreative, has been described as a “pragmatic creative with a unique ability to distill complex concepts into clear communications.” For 20+ years PJWCreative has provided strategic marketing and creative services for companies in industries such as biotech, technology, foodservice, retail and consumer goods. Penny works with principals to craft a compelling company story then translate that story to websites, investor decks, videos, infographics and social media. Prior to launching PJWCreative, Penny was VP Creative of a mid-sized agency, running a creative department serving top-tier national clients. An entrepreneur at heart, Penny has worked with start-up businesses and understands the unique challenges they face to communicate their messages to investors, media and potential business partners.
Opus Biotech Communication is proud to support the Biotech and Life Sciences industries as active members of
CONTACT
OPUS
